NanoVibronix’s UroShield trial results hold potential to advance urinary care: GlobalData

NanoVibronix has recently announced the successful completion of the pilot phase of its UroShield clinical trial in the US. The UroShield device is a novel ultrasonic technology that is designed to reduce catheter-associated complications such as infections, blockages, and discomfort. By generating low-frequency ultrasound waves, the device prevents bacterial colonisation and biofilm formation, addressing persistent challenges in urinary catheter management. The positive trial results will pave the way for broader clinical evaluation and could advance urinary care, says GlobalData.

According to GlobalData, the global urology therapy device market size is set to grow at a compound annual growth rate (CAGR) of 2.31 per cent from $9.23 billion in 2015 to $11.08 billion in 2033. This growth is fueled by several factors such as technological advancements in minimally invasive techniques and diagnostic tools, coupled with an aging population prone to urological conditions. Favorable healthcare policies and regulations further support market growth by encouraging the adoption of innovative technologies.

Graysen Vigneux, Medical Analyst at GlobalData, states, “The completion of the pilot phase in the US is a significant milestone for NanoVibronix. The UroShield device has the potential to improve the quality of life for patients requiring long-term catheterisation by addressing a critical unmet need in infection control and catheter management.”

The promising results of the US trial align with prior studies conducted in Europe, where UroShield demonstrated significant reductions in catheter-related infections and improved patient outcomes. These findings highlight the device’s potential to transform urinary care by offering a non-invasive, patient-friendly solution.

The reduction in catheter-associated infections not only benefits patients but also alleviates the financial burden on healthcare systems. Devices like UroShield could become a standard of care, reducing reliance on antibiotics and curbing the rise of antimicrobial resistance.”

Vigneux concludes, “NanoVibronix’s focus now shifts to securing FDA clearance and scaling production to meet anticipated demand in the US market. With increasing recognition of the impact of catheter-related complications, UroShield’s success could mark a turning point in the standard of care for urinary management.”